Juvenile Batten Disease Treatment BBDF-101 Earns FDA’s OK for Pre-Clinical Plan
The U.S. Food and Drug Administration (FDA) has given a favorable opinion of the continued preclinical development plan for BBDF-101, a potential new treatment for juvenile Batten disease (CLN3). The plan, made by Theranexus and the Beyond Batten Disease Foundation (BBDF), supports efforts to submit an…